74628-18-5

Basic information

• Product Name: 2-nitro-3-(piperidin-1-yl)aniline
• Synonyms: 2-nitro-3-(piperidin-1-yl)aniline
• CAS NO: 74628-18-5
• Molecular Weight: 221.259
• Mol File: 74628-18-5.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 2-nitro-3-(piperidin-1-yl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-nitro-3-(piperidin-1-yl)aniline(74628-18-5)
• EPA Substance Registry System: 2-nitro-3-(piperidin-1-yl)aniline(74628-18-5)

Safety Data

• Hazardous Substances Data: 74628-18-5(Hazardous Substances Data)

Upstream product

• 110-89-4 piperidine 
• 32114-57-1 2-nitro-m-phenylenediamine 
• 59483-54-4 3-chloro-2-nitro-aniline 
• 602-03-9 2,3-dinitroaniline 

Downstream Products

• 15822-77-2 1-(2-nitrophenyl)piperidine 

Relevant articles and documents

SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.